Primary completion· ClinicalTrials.gov
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Epcoritamab History and Updates
163 events · 2018 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
5
FDA Approvals
0
Label Revisions
158
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-12Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Epcoritamab since 2018, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (4)
2026
- FDA approval (supplemental)Epkinly Supplemental Efficacy Application Approved by FDA· Mar 27, 2026
2025
- FDA approval (supplemental)Epcoritamab (Epkinly) Receives FDA Supplemental Efficacy Approval· Nov 18, 2025
- Primary completionEpcoritamab Phase 3 R/R DLBCL Trial Scheduled for Primary Completion· Oct 13, 2025
- Primary completionEpcoritamab Phase 3 Trial for R/R DLBCL Reaches Primary Completion· Oct 13, 2025
Upcoming & expected milestones
Trial started· ClinicalTrials.gov
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Primary completion· ClinicalTrials.gov
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Primary completion· ClinicalTrials.gov
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Primary completion· ClinicalTrials.gov
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Primary completion· ClinicalTrials.gov
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relaps
Primary completion· ClinicalTrials.gov
Epcoritamab in Previously Treated WM
Primary completion· ClinicalTrials.gov
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphami
Primary completion· ClinicalTrials.gov
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Primary completion· ClinicalTrials.gov
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Primary completion· ClinicalTrials.gov
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Primary completion· ClinicalTrials.gov
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NH
Primary completion· ClinicalTrials.gov
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Primary completion· ClinicalTrials.gov
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Primary completion· ClinicalTrials.gov
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-
Primary completion· ClinicalTrials.gov
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Primary completion· ClinicalTrials.gov
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Primary completion· ClinicalTrials.gov
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Primary completion· ClinicalTrials.gov
Epco, Zanu, Ritux for R/R FL or MZL
Primary completion· ClinicalTrials.gov
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
Primary completion· ClinicalTrials.gov
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or
Primary completion· ClinicalTrials.gov
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Primary completion· ClinicalTrials.gov
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patient
Primary completion· ClinicalTrials.gov
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Primary completion· ClinicalTrials.gov
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Primary completion· ClinicalTrials.gov
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Primary completion· ClinicalTrials.gov
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed
Primary completion· ClinicalTrials.gov
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Primary completion· ClinicalTrials.gov
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Primary completion· ClinicalTrials.gov
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lympho
Primary completion· ClinicalTrials.gov
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of
Primary completion· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
Primary completion· ClinicalTrials.gov
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Primary completion· ClinicalTrials.gov
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Primary completion· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Primary completion· ClinicalTrials.gov
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment o
Primary completion· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Primary completion· ClinicalTrials.gov
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B
Primary completion· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous
Primary completion· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
Past events
2026
Trial started· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Trial registered· ClinicalTrials.gov
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Primary completion· ClinicalTrials.gov
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Trial started· ClinicalTrials.gov
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of
Trial registered· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Primary completion· ClinicalTrials.gov
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
FDA approval (supplemental)· FDA
Sponsor: GENMAB US, INC.. Class: Efficacy.
Trial started· ClinicalTrials.gov
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Trial registered· ClinicalTrials.gov
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Trial registered· ClinicalTrials.gov
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of
Trial started· ClinicalTrials.gov
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Trial started· ClinicalTrials.gov
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lympho
2025
Trial started· ClinicalTrials.gov
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment o
FDA approval (supplemental)· FDA
Sponsor: GENMAB US, INC.. Class: Efficacy.
Trial registered· ClinicalTrials.gov
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in C
Trial registered· ClinicalTrials.gov
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lympho
Trial started· ClinicalTrials.gov
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Primary completion· ClinicalTrials.gov
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in C
Trial started· ClinicalTrials.gov
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Primary completion· ClinicalTrials.gov
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Trial registered· ClinicalTrials.gov
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Trial started· ClinicalTrials.gov
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
FDA approval (supplemental)· FDA
Sponsor: GENMAB US, INC.. Class: Labeling.
Trial started· ClinicalTrials.gov
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Trial registered· ClinicalTrials.gov
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B
Trial started· ClinicalTrials.gov
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Trial started· ClinicalTrials.gov
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Trial registered· ClinicalTrials.gov
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Trial started· ClinicalTrials.gov
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B
Trial started· ClinicalTrials.gov
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or
Trial registered· ClinicalTrials.gov
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment o
Trial started· ClinicalTrials.gov
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Trial started· ClinicalTrials.gov
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Trial registered· ClinicalTrials.gov
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Trial started· ClinicalTrials.gov
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Trial started· ClinicalTrials.gov
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Primary completion· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard
Trial registered· ClinicalTrials.gov
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Trial registered· ClinicalTrials.gov
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Trial started· ClinicalTrials.gov
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Trial registered· ClinicalTrials.gov
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or
Trial started· ClinicalTrials.gov
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Trial registered· ClinicalTrials.gov
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Trial registered· ClinicalTrials.gov
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Trial started· ClinicalTrials.gov
Epco, Zanu, Ritux for R/R FL or MZL
Trial started· ClinicalTrials.gov
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
2024
Trial registered· ClinicalTrials.gov
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
Epcoritamab in Previously Treated WM
Trial started· ClinicalTrials.gov
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Trial registered· ClinicalTrials.gov
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Trial registered· ClinicalTrials.gov
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Trial started· ClinicalTrials.gov
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Trial registered· ClinicalTrials.gov
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Trial registered· ClinicalTrials.gov
Epco, Zanu, Ritux for R/R FL or MZL
Trial started· ClinicalTrials.gov
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
Results posted· ClinicalTrials.gov
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Trial registered· ClinicalTrials.gov
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Trial registered· ClinicalTrials.gov
Epcoritamab in Previously Treated WM
Trial registered· ClinicalTrials.gov
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Trial registered· ClinicalTrials.gov
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
FDA approval (supplemental)· FDA
Sponsor: GENMAB US, INC.. Class: Efficacy.
Trial registered· ClinicalTrials.gov
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Trial registered· ClinicalTrials.gov
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Trial registered· ClinicalTrials.gov
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Trial registered· ClinicalTrials.gov
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Trial started· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
Trial registered· ClinicalTrials.gov
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Trial started· ClinicalTrials.gov
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Trial started· ClinicalTrials.gov
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Trial started· ClinicalTrials.gov
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patient
Trial registered· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
2023
Trial started· ClinicalTrials.gov
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Trial registered· ClinicalTrials.gov
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Trial started· ClinicalTrials.gov
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-
Trial registered· ClinicalTrials.gov
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patient
Trial started· ClinicalTrials.gov
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Trial started· ClinicalTrials.gov
Epcoritamab and Rituximab for First-line Follicular Lymphoma
FDA approval· FDA
Sponsor: GENMAB US, INC.. Class: Type 1 - New Molecular Entity.
Trial registered· ClinicalTrials.gov
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-
Trial registered· ClinicalTrials.gov
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Trial registered· ClinicalTrials.gov
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Trial registered· ClinicalTrials.gov
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Trial started· ClinicalTrials.gov
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
Expanded Access Program for Epcoritamab
Trial started· ClinicalTrials.gov
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphami
Trial registered· ClinicalTrials.gov
Expanded Access to Epcoritamab
2022
Trial registered· ClinicalTrials.gov
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Trial registered· ClinicalTrials.gov
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphami
Trial started· ClinicalTrials.gov
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in C
Trial started· ClinicalTrials.gov
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed
Trial started· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
Trial started· ClinicalTrials.gov
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relaps
Trial registered· ClinicalTrials.gov
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relaps
Trial started· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous
Trial registered· ClinicalTrials.gov
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i
Trial registered· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous
Trial started· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard
Trial registered· ClinicalTrials.gov
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed
Trial registered· ClinicalTrials.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard
2021
Trial started· ClinicalTrials.gov
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2020
Trial registered· ClinicalTrials.gov
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial started· ClinicalTrials.gov
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Trial registered· ClinicalTrials.gov
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Trial registered· ClinicalTrials.gov
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Trial started· ClinicalTrials.gov
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial registered· ClinicalTrials.gov
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NH
Trial started· ClinicalTrials.gov
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NH
Trial registered· ClinicalTrials.gov
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Trial started· ClinicalTrials.gov
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
2018
Trial registered· ClinicalTrials.gov
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Trial started· ClinicalTrials.gov
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.